Preoperative insulin‐like growth factor‐binding protein‐3 (IGFBP‐3) blood level predicts gleason sum upgrading

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Prostate

• Publication date

  2012-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pros.21411PMID 21520165
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness

  2010cited by this paper
• The vanishing prostate cancer phenomenon.

  2010cited by this paper
• A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians.

  2010cited by this paper
• Urine biomarkers in prostate cancer

  2010cited by this paper
• Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer.

  2010cited by this paper
• The novel nomogram of Gleason sum upgrade: Possible application for the eligible criteria of low dose rate brachytherapy

  2010cited by this paper
• An update of the Gleason grading system.

  2010cited by this paper
• Androgens, growth factors, and risk of prostate cancer: The Multiethnic Cohort

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Identification of a Novel Cell Death Receptor Mediating IGFBP-3-induced Anti-tumor Effects in Breast and Prostate Cancer*

  2010cited by this paper
• Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen

  2009cited by this paper
• Insignificant prostate cancer and active surveillance: from definition to clinical implications.

  2009cited by this paper
• Predictive models in diagnosing indolent cancer

  2009cited by this paper
• Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system.

  2009cited by this paper
• A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score.

  2008cited by this paper
• Cytokine-based transformation of immune surveillance into tumor-promoting inflammation

  2008cited by this paper
• Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.

  2008cited by this paper
• Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

  2008cited by this paper
• Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment

  2007cited by this paper
• Prostate biopsy: current status and limitations.

  2007cited by this paper
• Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells

  2007cited by this paper
• Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens.

  2007cited by this paper
• Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology.

  2006cited by this paper
• Prostate Biopsy Volume Indices do not Predict for Significant Gleason Upgrading

  2005cited by this paper
• Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

  2005cited by this paper
• Are multiple markers the future of prostate cancer diagnostics?

  2004cited by this paper
• Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor β1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression

  2004cited by this paper
• Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma.

  2004cited by this paper
• Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.

  2004cited by this paper
• Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis

  2003cited by this paper
• Interleukin-6 biology is coordinated by membrane bound and soluble receptors.

  2003cited by this paper
• Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.

  2003cited by this paper
• Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.

  2002cited by this paper
• Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis.

  2002cited by this paper
• The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.

  2002cited by this paper
• Insulin-like Growth Factor (IGF)-binding Protein-3 Mutants That Do Not Bind IGF-I or IGF-II Stimulate Apoptosis in Human Prostate Cancer Cells*

  2002cited by this paper
• Comparison of Ultrasound-Guided Biopsies and Prostatectomy Specimens: Predictive Accuracy of Gleason Score and Tumor Site

  2001cited by this paper
• The soluble interleukin 6 receptor: mechanisms of production and implications in disease

  2001cited by this paper
• Internal validation of predictive models: efficiency of some procedures for logistic regression analysis.

  2001cited by this paper
• The development of androgen-independent prostate cancer

  2001cited by this paper
• Characterization of the inhibition of DNA synthesis in proliferating mink lung epithelial cells by insulin‐like growth factor binding protein‐3

  2000cited by this paper
• Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

  2000cited by this paper
• Patterns of prostate cancer biopsy grading: Trends and clinical implications

  2000cited by this paper
• Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities.

  2000cited by this paper
• Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians.

  2000cited by this paper
• Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

  2000cited by this paper
• Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy.

  1999cited by this paper
• Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain.

  1999cited by this paper
• Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer.

  1999cited by this paper
• Expression of Insulin-Like Growth Factor-2 Can Predict the Prognosis of Human Colorectal Cancer Patients: Correlation with Tumor Progression, Proliferative Activity and Survival

  1998cited by this paper
• Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer.

  1998cited by this paper
• Insulin‐like growth factor‐II as a prognostic factor in pulmonary adenocarcinoma

  1996cited by this paper
• Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth.

  1995cited by this paper
• Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer.

  1994cited by this paper
• Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer.

  1994cited by this paper
• The pathological features and prognosis of prostate cancer detectable with current diagnostic tests.

  1994cited by this paper
• Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate‐specific antigen levels

  1993cited by this paper
• Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma.

  1992cited by this paper
• Cell proliferation in carcinogenesis.

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• A review of goodness of fit statistics for use in the development of logistic regression models.

  1982cited by this paper

• Investigating periprostatic adipose tissue as a driving force of prostate cancer progression: a new source of information for the advancement of targeted therapy in metastatic prostate cancer

  2023cites this paper
• The Potential of Extracellular Matrix- and Integrin Adhesion Complex-Related Molecules for Prostate Cancer Biomarker Discovery

  2023cites this paper
• Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF‐1 upregulation of TUBB2B beta‐tubulin isoform

  2021cites this paper
• Optimized Identification of High-Grade Prostate Cancer by Combining Different PSA Molecular Forms and PSA Density in a Deep Learning Model

  2021cites this paper
• Bone morphogenetic protein 2 promotes human trophoblast cell invasion and endothelial‐like tube formation through ID1‐mediated upregulation of IGF binding protein‐3

  2020cites this paper
• Transcriptomic analysis of prostate cancer progression

  2018cites this paper
• Polyphyllin I inhibits invasion and epithelial-mesenchymal transition via CIP2A/PP2A/ERK signaling in prostate cancer.

  2018cites this paper
• Oncogenes and anti-oncogenes serve pivotal roles in the pathogenesis of several cancer types. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that suppresses protein phosphatase 2A (PP2A) activity in the degradation of c-Myc protein in cancer cells

  2018cites this paper
• IGFBP3 and MAPK/ERK signaling mediates melatonin‐induced antitumor activity in prostate cancer

  2017cites this paper
• BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people

  2017cites this paper
• Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance.

  2015cites this paper
• The Role of the IGF Axis in Epithelial-to-Mesenchymal Transition during the Progression of Prostate Cancer

  2015cites this paper
• Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer.

  2015cites this paper
• (2015). The role of the IGF axis in epithelial-to-mesenchymal transition during the progression of prostate cancer. Journal of Analytical Oncology

  2015cites this paper
• CEACAM5 is correlated with Angio/Lymphangiogenesis of Prostatic Lesions

  2014cites this paper
• IGFBP-3 Nuclear Localization Predicts Human Prostate Cancer Recurrence

  2013cites this paper
• Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene

  2011cites this paper